Research
Metabolic adaptation
GLP-1 RAs demonstrate multisystemic benefits including cardiovascular risk reduction and improved renal outcomes.
Incorporating GLP-1 RAs in treatment plans may enhance overall patient health beyond weight loss.
StrongSupportsmedium confidence
demonstrate multisystemic benefits including cardiovascular risk reduction, improved renal outcomes and treatment of metabolic-dysfunction-associated steatohepatitis.
Why this rating
The claim is based on a synthesis of current evidence presented in the review.
Source
Obesity management medications for the surgeon
Matthew Harris et al. · Frontline Gastroenterology · 2026
review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →